Static tool

Condition-to-molecule map

Matrix view of 13 metabolic conditions against the peptide molecules in this registry, showing where reported trial evidence or a licensed indication exists for each pairing.

By Metabolic Peptides Editorial TeamReviewed by Scientific Review PanelLast updated 21 May 2026

Studied — condition appears in the molecule's reported trial evidence in this registry. Cell links to the condition page; where a key trial is listed, a “+trial” link is shown.

Licensed — the molecule's licensed-indications summary contains a keyword associated with this condition. A licensed indication for one population is not a licensed indication for every patient or context.

Condition	Tirzepatide	Semaglutide	Liraglutide	Dulaglutide	Retatrutide	Cagrilintide	CagriSema	Survodutide	Mazdutide	Pemvidutide	Cotadutide	Tesamorelin	CJC-1295 / Ipamorelin	AOD-9604	HGH Fragment 176-191	Orforglipron	Danuglipron	MariTide (AMG 133)	Pramlintide	Exenatide	Efpeglenatide
Type 2 diabetes	●+trial	●+trial	●+trial	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	★	★	–
Obesity	●+trial	●+trial	●+trial	–	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Prediabetes	●+trial	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Metabolic syndrome	●+trial	●+trial	–	–	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
MASLD / MASH (metabolic dysfunction-associated steatotic liver disease)	●+trial	●+trial	–	–	●+trial	–	–	●+trial	–	●+trial	–	–	–	–	–	–	–	–	–	–	–
Obstructive sleep apnoea (OSA)	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Heart failure with preserved ejection fraction (HFpEF)	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Cardiovascular risk	●+trial	●+trial	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	★	–
Chronic kidney disease (CKD)	–	●+trial	–	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
HIV-associated lipodystrophy	–	–	–	–	–	–	–	–	–	–	–	●	–	–	–	–	–	–	–	–	–
Visceral adiposity	●+trial	●+trial	–	–	●+trial	–	–	–	–	–	–	●+trial	–	–	–	–	–	–	–	–	–
Sarcopenic obesity and lean-mass concerns	●+trial	●+trial	–	–	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Post-weight-loss maintenance	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Weight regain after GLP-1 discontinuation	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Polycystic ovary syndrome (PCOS)	●+trial	●+trial	●+trial	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

What this matrix does not establish

Matrix cells indicate where evidence has been reported in published trials or in the licensed-indications text; they do not constitute endorsement, treatment recommendation, or clinical guidance.
A licensed indication for one population is not a licensed indication for any other population or condition — the ★ marker reflects keyword overlap in the indications summary, not a clinical claim.
Blank cells mean no relationship was identified in the current registry; they are not proof of absence of evidence elsewhere in the literature.
Investigational and research-only molecules have no licensed human therapeutic indication; trial evidence listed is from registered clinical programmes only.
This matrix does not provide dosing, prescribing, or self-experimentation guidance.

Last reviewed 21 May 2026 · condition-to-molecule map · Metabolic Peptides editorial team